Efficacy and Safety of Insulin Glargine Combined with Sitagliptin in Elderly Type 2 Diabetes Patients with Poor Glycemic Control
- VernacularTitle:甘精胰岛素与西格列汀联用治疗口服降糖药控制不佳的老年2型糖尿病的有效性和安全性
- Author:
Yakun KONG
;
Xiuqin GENG
;
Yanhong ZHOU
;
Yufeng CHEN
;
Zhenyun GUO
- Publication Type:Journal Article
- Keywords:
Glargine;
Sitagliptin;
Elderly;
Type 2 diabetes;
Diabetic education
- From:
China Pharmacist
2016;19(4):695-697
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of insulin glarsine combined with sitagliptin in elderly type 2 diabetic patients whose blood glucose levels were inadequately controlled by oral anti-diabetic drugs ( OAD) . Methods: In the open-labeled, randomized and parallel study, 98patients (≥60 years) were randomly divided into two groups: insulin glargine/sitagliptin combina-tion group (n=52, the observation group ) and insulin Aspart 30 injection group (n=46, the control group). The dose was adjusted according to the blood glucose. The fasting blood glucose (FBG), 2h postprandial blood glucose (2hPBG), glycosylated hemoglobin (HbA1c), the incidence of hypoglycemia and body mass index (BMI) after the 12-week treatment were compared between the two groups. Results:The fasting glucose and the incidence of hypoglycemia in the observation group were lower than those in the control group (P<0. 05). There were no significant differences in 2h postprandial blood glucose, HbA1c and BMI between the two groups (P>0. 05). Conclusion:The treatment of insulin glargine combined with sitagliptin is safe, effective and convenient in elderly type 2 diabetes patients with poor glycemic control. By diabetic education, the lower incidence of hypoglycemia treatment will be a better choice for elderly type 2 diabetic patients.
